CLEAR PHARMA is altering the commercialization methodology for drug treatments of rare diseases.
Our radical collaboration platform creates an advanced interdependent community among individual and institutional healthcare stakeholders – from patients to pharma.
Our solutions are driven by an inter-woven customized process —ClearPath® by our Axxience cross-functional team— combining critical knowledge-based commercialization solutions demanded by rare diseases.
Waiting until Phase III to commence commercialization efforts will compromise product and company success. Engaging the disparate rare-disease stakeholder community and commencing scientific and access planning in Phase II will assist in development, funding and approval while increasing awareness and demand resulting in a well—informed community and faster uptake upon launch.